Do analysts prefer BCDA or TRIB?

BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 2,740.91%. Given BioCardia's stronger consensus rating and higher probable upside, equities analysts plainly believe BioCardia is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BCDA or TRIB more profitable?

BioCardia has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Trinity Biotech -85.36% N/A -36.61%

Does the media favor BCDA or TRIB?

In the previous week, BioCardia had 10 more articles in the media than Trinity Biotech. MarketBeat recorded 12 mentions for BioCardia and 2 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.46 beat BioCardia's score of -0.09 indicating that Trinity Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TRIB or MTVA?

MetaVia has a consensus price target of $20.00, suggesting a potential upside of 1,049.43%. Given MetaVia's stronger consensus rating and higher possible upside, analysts clearly believe MetaVia is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TRIB or MTVA more profitable?

MetaVia has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Trinity Biotech -85.36% N/A -36.61% MetaVia N/A -172.92% -89.39%

Does the media prefer TRIB or MTVA?

In the previous week, MetaVia had 2 more articles in the media than Trinity Biotech. MarketBeat recorded 4 mentions for MetaVia and 2 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.46 beat MetaVia's score of 0.35 indicating that Trinity Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RVPH or TRIB?

In the previous week, Trinity Biotech had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Trinity Biotech and 1 mentions for Reviva Pharmaceuticals. Trinity Biotech's average media sentiment score of 1.46 beat Reviva Pharmaceuticals' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TRIB or NXTC?

NextCure has a consensus price target of $23.00, suggesting a potential upside of 1,005.77%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 NextCure 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is TRIB or NXTC more profitable?

NextCure has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Trinity Biotech -85.36% N/A -36.61% NextCure N/A -186.96% -124.62%

Do analysts prefer TRIB or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Trinity Biotech (TRIB) Competitors

$0.65 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.66 +0.01 (+0.77%)

As of 06/12/2026 06:57 PM Eastern

Compare

TRIB vs. BCDA, MTVA, RVPH, NXTC, and CURX

Should you buy Trinity Biotech stock or one of its competitors? MarketBeat compares Trinity Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trinity Biotech include BioCardia (BCDA), MetaVia (MTVA), Reviva Pharmaceuticals (RVPH), NextCure (NXTC), and Curanex Pharmaceuticals (CURX). These companies are all part of the "pharmaceutical products" industry.

How does Trinity Biotech compare to BioCardia?

BioCardia (NASDAQ:BCDA) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

BioCardia has higher earnings, but lower revenue than Trinity Biotech. BioCardia is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	166.91	-$8.23M	-$0.91	N/A
Trinity Biotech	$43.79M	0.05	-$37.38M	-$3.90	N/A

BioCardia has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Trinity Biotech	-85.36%	N/A	-36.61%

In the previous week, BioCardia had 10 more articles in the media than Trinity Biotech. MarketBeat recorded 12 mentions for BioCardia and 2 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.46 beat BioCardia's score of -0.09 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trinity Biotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCardia currently has a consensus target price of $25.00, indicating a potential upside of 2,740.91%. Given BioCardia's stronger consensus rating and higher probable upside, equities analysts plainly believe BioCardia is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioCardia beats Trinity Biotech on 9 of the 15 factors compared between the two stocks.

How does Trinity Biotech compare to MetaVia?

Trinity Biotech (NASDAQ:TRIB) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, MetaVia had 2 more articles in the media than Trinity Biotech. MarketBeat recorded 4 mentions for MetaVia and 2 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 1.46 beat MetaVia's score of 0.35 indicating that Trinity Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MetaVia has lower revenue, but higher earnings than Trinity Biotech. MetaVia is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.79M	0.05	-$37.38M	-$3.90	N/A
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A

MetaVia has a consensus price target of $20.00, suggesting a potential upside of 1,049.43%. Given MetaVia's stronger consensus rating and higher possible upside, analysts clearly believe MetaVia is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MetaVia has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-85.36%	N/A	-36.61%
MetaVia	N/A	-172.92%	-89.39%

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 0.6% of MetaVia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Trinity Biotech beats MetaVia on 8 of the 14 factors compared between the two stocks.

How does Trinity Biotech compare to Reviva Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Trinity Biotech had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Trinity Biotech and 1 mentions for Reviva Pharmaceuticals. Trinity Biotech's average media sentiment score of 1.46 beat Reviva Pharmaceuticals' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trinity Biotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Reviva Pharmaceuticals has higher earnings, but lower revenue than Trinity Biotech. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Trinity Biotech	$43.79M	0.05	-$37.38M	-$3.90	N/A

Reviva Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Trinity Biotech	-85.36%	N/A	-36.61%

Reviva Pharmaceuticals presently has a consensus price target of $66.67, indicating a potential upside of 9,648.01%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Trinity Biotech beats Reviva Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Trinity Biotech compare to NextCure?

Trinity Biotech (NASDAQ:TRIB) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NextCure has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-85.36%	N/A	-36.61%
NextCure	N/A	-186.96%	-124.62%

NextCure has a consensus price target of $23.00, suggesting a potential upside of 1,005.77%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
NextCure	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Trinity Biotech has higher revenue and earnings than NextCure. Trinity Biotech is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.79M	0.05	-$37.38M	-$3.90	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

In the previous week, Trinity Biotech and Trinity Biotech both had 2 articles in the media. NextCure's average media sentiment score of 1.93 beat Trinity Biotech's score of 1.46 indicating that NextCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Trinity Biotech	Positive
NextCure	Very Positive

Summary

NextCure beats Trinity Biotech on 7 of the 13 factors compared between the two stocks.

How does Trinity Biotech compare to Curanex Pharmaceuticals?

Trinity Biotech (NASDAQ:TRIB) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Trinity Biotech had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 2 mentions for Trinity Biotech and 1 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.87 beat Trinity Biotech's score of 1.46 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Trinity Biotech	Positive
Curanex Pharmaceuticals	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals has lower revenue, but higher earnings than Trinity Biotech. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.79M	0.05	-$37.38M	-$3.90	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

79.0% of Trinity Biotech shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Curanex Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-85.36%	N/A	-36.61%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Summary

Trinity Biotech beats Curanex Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Trinity Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRIB vs. The Competition

Export

Metric	Trinity Biotech	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.34M	$8.31B	$6.52B	$12.05B
Dividend Yield	N/A	2.50%	2.67%	5.66%
P/E Ratio	-0.17	15.64	24.00	24.42
Price / Sales	0.05	7.06	515.84	118.72
Price / Cash	N/A	17.44	27.48	37.92
Price / Book	-0.03	3.62	10.60	6.82
Net Income	-$37.38M	$224.06M	$3.57B	$337.56M
7 Day Performance	-4.41%	-1.40%	0.59%	1.16%
1 Month Performance	13.16%	4.39%	1.54%	3.16%
1 Year Performance	-79.75%	-0.88%	25.41%	30.60%

Trinity Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRIB Trinity Biotech	0.9171 of 5 stars	$0.65 flat	N/A	-79.8%	$2.34M	$43.79M	N/A	480	Positive News High Trading Volume
BCDA BioCardia	3.4983 of 5 stars	$0.86 -7.0%	$25.00 +2,820.6%	-59.6%	$9.78M	$60K	N/A	40	Gap Down
MTVA MetaVia	2.1238 of 5 stars	$1.88 -15.3%	$20.00 +963.8%	-78.4%	$9.72M	N/A	N/A	8	Gap Down
RVPH Reviva Pharmaceuticals	2.2862 of 5 stars	$0.71 +3.1%	$66.67 +9,276.5%	-95.3%	$9.32M	N/A	N/A	5	News Coverage Analyst Upgrade
NXTC NextCure	3.5837 of 5 stars	$2.57 -8.1%	$23.00 +796.7%	-74.5%	$9.26M	N/A	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRIB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trinity Biotech (TRIB) Competitors

TRIB vs. BCDA, MTVA, RVPH, NXTC, and CURX

How does Trinity Biotech compare to BioCardia?

Summary

How does Trinity Biotech compare to MetaVia?

Summary

How does Trinity Biotech compare to Reviva Pharmaceuticals?

Summary

How does Trinity Biotech compare to NextCure?

Summary

How does Trinity Biotech compare to Curanex Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trinity Biotech (TRIB) Competitors

TRIB vs. BCDA, MTVA, RVPH, NXTC, and CURX

How does Trinity Biotech compare to BioCardia?

Which has preferable valuation & earnings, BCDA or TRIB?

Is BCDA or TRIB more profitable?

Does the media favor BCDA or TRIB?

Do analysts prefer BCDA or TRIB?

Do institutionals and insiders hold more shares of BCDA or TRIB?

Summary

How does Trinity Biotech compare to MetaVia?

Does the media prefer TRIB or MTVA?

Which has preferable valuation & earnings, TRIB or MTVA?

Do analysts prefer TRIB or MTVA?

Is TRIB or MTVA more profitable?

Do insiders & institutionals hold more shares of TRIB or MTVA?

Summary

How does Trinity Biotech compare to Reviva Pharmaceuticals?

Does the media favor RVPH or TRIB?

Which has preferable earnings & valuation, RVPH or TRIB?

Is RVPH or TRIB more profitable?

Do analysts rate RVPH or TRIB?

Do insiders & institutionals have more ownership in RVPH or TRIB?

Summary

How does Trinity Biotech compare to NextCure?

Do institutionals & insiders hold more shares of TRIB or NXTC?

Is TRIB or NXTC more profitable?

Do analysts prefer TRIB or NXTC?

Which has higher valuation & earnings, TRIB or NXTC?

Does the media prefer TRIB or NXTC?

Summary

How does Trinity Biotech compare to Curanex Pharmaceuticals?

Does the media prefer TRIB or CURX?

Do analysts prefer TRIB or CURX?

Which has preferable earnings and valuation, TRIB or CURX?

Do insiders & institutionals hold more shares of TRIB or CURX?

Is TRIB or CURX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools